LifeMD (NASDAQ:LFMD) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS

LifeMD (NASDAQ:LFMD) announced its earnings results on Thursday. The company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.14) by $0.03, FiscalAI reports. LifeMD had a negative return on equity of 168.23% and a net margin of 0.10%. The business had revenue of $44.63 million during the quarter, compared to the consensus estimate of $48.84 million.

Here are the key takeaways from LifeMD’s conference call:

• Third-quarter revenue was $44.6 million, below guidance of $48 million–$51 million and down about 7% year over year. LifeMD cut its 2026 revenue outlook to $188 million–$191 million from $205.5 million–$212.5 million and now expects an adjusted EBITDA loss of $10.6 million–$12.6 million.
• LifeMD finalized arrangements with Eli Lilly and Novo Nordisk to fulfill and ship branded GLP-1 medications through its pharmacy, potentially adding revenue and gross profit dollars from prescriptions it previously fulfilled through third parties. Management cautioned that gross margin percentage will decline as branded-drug revenue is reported on a gross basis.
• Management said customer acquisition cost fell 40% from its June peak, while the share of new Weight Management patients choosing multi-month plans rose from about 25% to 85%. Active subscribers were up 13% year over year and nearly flat sequentially despite a 34% quarter-over-quarter reduction in selling and marketing expense.
• The AT&T collaboration is live in 11 states, reaching about 29 million customers, with nationwide rollout expected in January; the company also plans to market its enterprise offering to employers. Management described these as lower-cost growth opportunities, but said they were not included in fourth-quarter guidance and will report traction as they scale.
• LifeMD ended the quarter with $21.9 million in cash and no debt, then closed a $12.5 million term loan to support working-capital needs. It is targeting a 25% reduction in operating expenses by the first quarter of 2027 and said it expects roughly 30% revenue and patient growth in 2027 on about the same fixed overhead.

LifeMD Price Performance

LFMD traded up $0.38 on Friday, reaching $2.04. 4,697,469 shares of the company traded hands, compared to its average volume of 1,028,117. The stock’s 50 day moving average price is $2.62 and its 200-day moving average price is $3.58. LifeMD has a 52-week low of $1.60 and a 52-week high of $5.38. The company has a market cap of $98.09 million, a price-to-earnings ratio of -40.69 and a beta of 2.19.

Analysts Set New Price Targets

Several analysts have issued reports on the company. KeyCorp set a $5.00 price objective on LifeMD and gave the stock an “overweight” rating in a report on Friday, August 7th. Weiss Ratings reissued a “sell (d)” rating on shares of LifeMD in a research report on Monday, November 2nd. B. Riley Financial started coverage on shares of LifeMD in a report on Friday, September 11th. They set a “buy” rating and a $8.00 price target on the stock. Wall Street Zen downgraded shares of LifeMD from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Finally, BTIG Research reduced their price target on shares of LifeMD from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $7.43.

Key LifeMD News

These are some of the LFMD news items that stood out recently:

• Positive Sentiment: LifeMD’s Q3 loss of $0.11 per share was narrower than the $0.14 loss analysts expected. Adjusted EBITDA loss was about $0.4 million, within company guidance and a roughly $3.1 million sequential improvement, driven mainly by lower selling, marketing, and other non-clinical expenses. LifeMD Reports Third Quarter 2026 Results
• Negative Sentiment: Q3 revenue of $44.6 million missed analysts’ $48.84 million estimate. The company also forecast Q4 revenue of $46 million–$49 million, well below the $61.4 million consensus, and 2026 revenue of $188 million–$191 million versus the $207.6 million consensus. The weaker outlook could weigh on expectations for growth. LifeMD Q3 Results and Revenue Miss
• Neutral Sentiment: A transcript of LifeMD’s Q3 earnings call was published, offering investors additional management commentary. Q3 2026 Earnings Call Transcript

About LifeMD

LifeMD, Inc. is a virtual healthcare company that connects patients with medical providers through its telehealth platform. Its services include virtual primary care and specialty care, with offerings in areas such as men’s health and weight management. The company operates the LifeMD and Rex MD brands and supports care through online consultations, treatment plans and, when prescribed, medication. Service availability and treatment options may vary by state and individual patient needs. LifeMD serves patients in the United States.